To hear about similar clinical trials, please enter your email below
Trial Title:
A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma
NCT ID:
NCT05852028
Condition:
Lymphoma
DLBCL
T Cell Lymphoma
Conditions: Official terms:
Lymphoma
Lymphoma, Non-Hodgkin
Conditions: Keywords:
SELINEXOR
LYMPHOMA
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Drug
Intervention name:
Selinexor
Description:
this is a real-world. Patients who use selinexor-based regimens in lymphoma will be
followed up without interfering with the choice of treatment options for patients
Arm group label:
selinexor-based regimens
Other name:
XPO1 inhibitor
Summary:
This study aims to observe and explore the efficacy and safety of selinexor-based regimen
in patients with Non-Hodgkin lymphoma
Detailed description:
this study aims to observe and explore the efficacy and safety of selinexor-based regimen
in patients with DLBCL or T cell lymphoma. This study is a non-interventional real world,
observational study and all registered data are collected from real clinical practice
cases. The medical data includes patient demographic, tumor characteristics, laboratory
examination, history of treatments, adverse reactions, efficacy results and possible
prognostic factors.
Criteria for eligibility:
Study pop:
DLBCL, T or NK cell lymphoma
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Know and voluntarily sign the Informed Consent Form (ICF)
- Clinically confirmed DLBCL, T or NK cell lymphoma
- Patients with DLBCL or T or NK cell lymphoma who have used selinexor-based therapy
in the past 3 months are included
- Cooperate with clinical diagnosis and treatment management, and provide
disease-related past medical history materials
Exclusion Criteria:
- Previously received selinexor
- Poor patient compliance
- physicians evaluate that patients are not suitable for enrollment
Gender:
All
Minimum age:
N/A
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Address:
City:
Shanghai
Zip:
200025
Country:
China
Status:
Recruiting
Contact:
Last name:
Weili Zhao, M.D. and Ph.D
Phone:
13512112076
Email:
zhao.weili@yahoo.com
Facility:
Name:
The First Affiliated Hospital of Soochow University
Address:
City:
Suzhou
Country:
China
Status:
Recruiting
Contact:
Last name:
Depei Wu, Prof.
Facility:
Name:
Union Hospital Affiliated to Huazhong University of Science and Technology
Address:
City:
Wuhan
Country:
China
Status:
Recruiting
Contact:
Last name:
Yu Hu, Prof.
Start date:
December 15, 2022
Completion date:
October 18, 2025
Lead sponsor:
Agency:
Ruijin Hospital
Agency class:
Other
Source:
Ruijin Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05852028
